Johnson & Johnson bets on robotic technologies – analysts see a 15% rise in the company's share price
The future belongs to stable trends, global changes in various areas, which give a strong impetus for the development of individual sectors and industries. Understanding these changes and identifying the companies that will benefit from future growth means providing your investments with serious double-digit returns over a 10-15 year horizon.
Johnson & Johnson, one of the world's largest diversified healthcare corporations, is committed to keeping up with the times by investing in future-proof robotic technologies. According to the report on financial results of the American company Johnson & Johnson for the second quarter of 2019, the company's sales amounted to $ 20.6 billion.
In 2019, Johnson & Johnson announced on its official website that it had acquired Auris Health, Inc., which specializes in the development of robotic technologies primarily targeted at lung cancer. Auris Health, Inc.'s platform is currently used in bronchoscopic diagnostic and therapeutic procedures and is also FDA-cleared.
The acquisition of Auris Health, Inc. will accelerate Johnson & Johnson's entry into the robotics segment and create growth potential for the company. According to the terms of the deal, the total cost of the acquisition is estimated at $ 3.4 billion. The global market for robotics services could reach $ 34.7 billion by 2022, according to analysts from Allied Market Research.
Johnson & Johnson has a market cap of $ 349.20 billion.
According to Wall Street analysts, the average TP for Johnson & Johnson (JNJ) shares is $ 151.9 (+ 15%). Growth is likely to be much higher in 2020.
Johnson & Johnson (JNJ) shares are up 22% in 5 years.